-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 22, Zhejiang Medicine issued an announcement stating that its subsidiary, Zhejiang Xinma Biomedicine Co.
Recombinant humanized anti-CD70 monoclonal antibody-AS269 conjugate (ARX305) for injection is a new generation of monoclonal antibody conjugate drug developed by the company on October 22, 2019, which signed the "Cooperative Development and License Agreement" with Ambrx in the United States.
As of November 30, 2021, the company's ARX305 project has invested a total of 65.
CD70 is a member of the tumor necrosis factor receptor (TNFR) superfamily.
The CD70 monoclonal antibodies that have been or are being developed abroad include MDX1411, ARGX-110 and SEA-CD70, and ADCs include SGN-75, SGN-CD70A, MDX-1203 and AMG172.
At present, there is no marketed drug targeting CD70 at home and abroad
Cancer is one of the most important public health problems in the 21st century, with high morbidity and mortality rates worldwide